Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01166074 · ClinicalTrials.gov registry record
Retrospective Chart Review of Subcutaneous IgG Use in Infants
A clinical trial, sponsored by CSL Behring.
- Completed
- Registry status
- 27
- Enrollment target
NCT01166074: Completed study, sponsored by CSL Behring.
NCT01166074 is a clinical trial that has completed, run by CSL Behring. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01166074 has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
Study Summary
This study is a retrospective chart review of the use of subcutaneous IgG (SCIG) in infants less than two years old.
Primary Outcome
To describe the use of SCIG in infants below the age of two years in major academic medical centers and immunologists' practices in the US
Interventions
- BIOLOGICAL Subcutaneous IgG (SCIG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-12 |
What the finished NCT01166074 record still lists
NCT01166074 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Subcutaneous IgG (SCIG) is the first listed.
NCT01166074 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01166074 about?
NCT01166074 is a clinical study titled "Retrospective Chart Review of Subcutaneous IgG Use in Infants". This study is a retrospective chart review of the use of subcutaneous IgG (SCIG) in infants less than two years old.
What is the current status of trial NCT01166074?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2010-05. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01166074?
The interventions under investigation include: Subcutaneous IgG (SCIG) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01166074?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia